Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909. (scientific article)

A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults

Q33598040

Growth-inhibitory antibodies are not necessary for protective immunity to malaria infection

Q33613813

In vitro growth-inhibitory activity and malaria risk in a cohort study in mali

Q33613892

Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria

Q33788306

Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara

Q33935092

The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals

Q34021580

High diversity and rapid changeover of expressed var genes during the acute phase of Plasmodium falciparum infections in human volunteers

Q34075564

In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response

Q34260615

Blood stage vaccines for Plasmodium falciparum: current status and the way forward

Q34663978

Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity

Q34975629

Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines

Q36477537

Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update

Q36835613

Cell-mediated immunity elicited by the blood stage malaria vaccine apical membrane antigen 1 in Malian adults: results of a Phase I randomized trial

Q37253541

Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay

Q37256085

A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali

Q37267850

A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals

Q37294887

Inhibitory antibodies specific for the 19-kilodalton fragment of merozoite surface protein 1 do not correlate with delayed appearance of infection with Plasmodium falciparum in semi-immune individuals in Vietnam

Q37355849

Blood-stage malaria vaccines - recent progress and future challenges

Q37761208

Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites

Q38900364

Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers

Q39163542

Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum

Q39362892

Blood-stage challenge for malaria vaccine efficacy trials: a pilot study with discussion of safety and potential value.

Q39428067

Population dynamics of untreated Plasmodium falciparum malaria within the adult human host during the expansion phase of the infection

Q39465428

Multiple functions of human T cells generated by experimental malaria challenge

Q39527151

Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection

Q39571557

Substantially reduced pre-patent parasite multiplication rates are associated with naturally acquired immunity to Plasmodium falciparum

Q42127731

Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes

Q42938913

Malaria. Did they really say ... eradication?

Q44139004

Report of a consultation on the optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines, 18-19 March 2009, Bethesda, MD, USA.

Q44147443

Testing vaccines in human experimental malaria: statistical analysis of parasitemia measured by a quantitative real-time polymerase chain reaction

Q44161485

Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials.

Q44165291

Measurement of Plasmodium falciparum growth rates in vivo: a test of malaria vaccines

Q45037329

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

Q45723463

Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa

Q47309532

The potential role of vaccines in the elimination of falciparum malaria and the eventual eradication of malaria

Q47918371

P275

Creative Commons CC0 License

Q6938433

P6216

copyrighted, dedicated to the public domain by copyright holder

Q88088423

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

malaria

Q12156

malaria vaccine

Q6741353

P304

page(s)

e22271

P577

publication date

2011-07-22

P1433

published in

PLOS One

Q564954

P1476

title

Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909.

P478

volume

Reverse relations

cites work (P2860)

Q47547431	A controlled human malaria infection model enabling evaluation of transmission-blocking interventions
Q38626558	A malaria vaccine protects Aotus monkeys against virulent Plasmodium falciparum infection
Q28476638	A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs
Q34257253	Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure
Q36903515	Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infection
Q97548491	Bliss' and Loewe's additive and synergistic effects in Plasmodium falciparum growth inhibition by AMA1-RON2L, RH5, RIPR and CyRPA antibody combinations
Q38607840	Building an effective malaria vaccine pipeline to address global needs
Q36391845	Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy?
Q37530299	Challenges of assessing the clinical efficacy of asexual blood-stage Plasmodium falciparum malaria vaccines
Q37334935	Changes in Serological Immunology Measures in UK and Kenyan Adults Post-controlled Human Malaria Infection
Q34613585	Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer
Q34600955	Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial
Q38607982	Comparison of statistical models to estimate parasite growth rate in the induced blood stage malaria model
Q44168331	Controlled Human Malaria Infection: Applications, Advances and Challenges.
Q38001604	Controlled human blood stage malaria infection: current status and potential applications
Q36871970	Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01
Q37530123	Determining the validity of hospital laboratory reference intervals for healthy young adults participating in early clinical trials of candidate vaccines
Q38096490	Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials.
Q35354508	Development of cultured Plasmodium falciparum blood-stage malaria cell banks for early phase in vivo clinical trial assessment of anti-malaria drugs and vaccines
Q30416005	Distinguishing malaria and influenza: early clinical features in controlled human experimental infection studies
Q36384456	Enhancing blockade of Plasmodium falciparum erythrocyte invasion: assessing combinations of antibodies against PfRH5 and other merozoite antigens
Q28538917	External quality assurance of malaria nucleic acid testing for clinical trials and eradication surveillance
Q36933639	Immunogenicity of a peptide-based anti-IgE conjugate vaccine in non-human primates
Q37199873	Infectivity of Plasmodium falciparum in Malaria-Naive Individuals Is Related to Knob Expression and Cytoadherence of the Parasite
Q37643896	Invasion-inhibitory antibodies elicited by immunization with Plasmodium vivax apical membrane antigen-1 expressed in Pichia pastoris yeast
Q26772878	Merozoite surface proteins in red blood cell invasion, immunity and vaccines against malaria
Q26700078	Neutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic Review
Q38065630	New approaches to studying Plasmodium falciparum merozoite invasion and insights into invasion biology
Q36826951	Overcoming allelic specificity by immunization with five allelic forms of Plasmodium falciparum apical membrane antigen 1.
Q37981769	Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants
Q34441098	Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria
Q28731894	Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors
Q38059751	Plasmodium falciparum malaria vaccines: current status, pitfalls and future directions
Q28066456	Plasmodium vivax Controlled Human Malaria Infection - Progress and Prospects
Q56342201	Production, quality control, stability, and potency of cGMP-produced RH5.1 protein vaccine expressed in S2 cells
Q47111142	Profiling invasive Plasmodium falciparum merozoites using an integrated omics approach
Q37025030	Progress and prospects for blood-stage malaria vaccines
Q36394177	Progress with viral vectored malaria vaccines: A multi-stage approach involving "unnatural immunity".
Q36835495	Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity
Q36394182	Recent advances in recombinant protein-based malaria vaccines
Q38168903	Recent progress concerning CpG DNA and its use as a vaccine adjuvant
Q36064542	Standardization of the antibody-dependent respiratory burst assay with human neutrophils and Plasmodium falciparum malaria
Q47875868	T-bet modulates the antibody response and immune protection during murine malaria
Q34241973	The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody
Q47400686	Transcriptomics in Human Challenge Models
Q39296506	Vaccines to Accelerate Malaria Elimination and Eventual Eradication

P819	ADS bibcode	2011PLoSO...622271D
P356	DOI	10.1371/JOURNAL.PONE.0022271
P932	PMC publication ID	3142129
P698	PubMed publication ID	21799809
P5875	ResearchGate publication ID	51531213